Seoul Economic Daily EnglishCodex · 实盘不做把握 7/10
北京时间·🕒 发布 08:33:25时区推断·⟳ 抓取 08:53:23·⚡ 决策 07-20 13:14:13 +4h20m·99.3 天前
HLB美国子公司Immunomic启动ITI-5000三阴乳腺癌疫苗美国1期首例给药
这是早期1期首例给药，主要验证安全性和免疫反应，距离疗效读出、注册和商业化仍很远。
📄 原文Seoul Economic Daily English↗ 原文
HLB Unit Immunomic Doses First Patient in U.S. Phase 1 Cancer Vaccine Trial
Immunomic Therapeutics (Immunomic), the U.S. subsidiary of HLB (028300.KQ), is stepping up development of its cancer va…
不做 HLB（028300.KQ）
ITI-5000只是1期首例给药，IND和试验登记此前已公开，尚无疗效或商业化量级，且HLB盘中下跌显示市场未确认利好，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- ITI-5000的VITAL-TNBC 1期试验记录已公开，显示试验目标是安全性、耐受性和免疫原性。
- 韩国医药媒体报道HLB子公司Immunomic已于美国当地7月16日完成ITI-5000首例给药。
- 韩国财经媒体继续扩散同一首例给药进展，确认这是1月IND后的临床执行节点。
- 2026-07-20 05:13 UTC市场反应stock_quote非一手HLB（028300.KQ）最新价31000韩元，较前收35300韩元下跌12.18%，未形成利好重定价。市场反应:028300.KQ -12.18%
关键理由
- 这是早期1期首例给药，主要验证安全性和免疫反应，距离疗效读出、注册和商业化仍很远。
- ITI-5000的IND已在2026年1月获批，ClinicalTrials.gov在6月已公开试验设计，本次只是临床执行进展而非新的注册或销售里程碑。
- HLB（028300.KQ）盘中反而下跌约12%，说明市场没有把该消息定价为可交易的短线利好。
主要风险
- 若后续披露早期免疫反应或客观缓解率超预期，可能重新形成新的临床数据催化。
- HLB近期波动极端，单日涨跌停级别波动可能使任何追随早期临床新闻的交易胜率较差。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中与本次首例给药相关的收入量级或商业化进展证据。
检索:HLB Immunomic ITI-5000 Phase 1 triple-negative breast cancer first patient - 做多前查反向 · 来源 stock_quote · 日期 2026-07-20 · 影响 weakens
HLB盘中下跌12.18%，近期波动极端，价格行为不支持把早期临床执行节点作为做多催化。
检索:028300.KQ stock_quote full
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,476 字
Immunomic Therapeutics (Immunomic), the U.S. subsidiary of HLB (028300.KQ), is stepping up development of its cancer vaccine candidate "ITI-5000."
HLB said on the 20th that Immunomic had begun dosing the first patient in a U.S. Phase 1 clinical trial of ITI-5000, a therapeutic cancer vaccine candidate for triple-negative breast cancer (TNBC). Immunomic received approval for its Phase 1 investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) in January this year.
In the trial, Immunomic will evaluate the safety, tolerability and early immunological activity of ITI-5000 in patients with stage 2-3 triple-negative breast cancer. The company decided to test the candidate both as a monotherapy and in combination with standard adjuvant therapy.
ITI-5000 is a cancer vaccine candidate that applies self-amplifying RNA (saRNA) technology based on "UNITE," an immunotherapy vaccine platform independently developed by Immunomic. It is designed to induce a T-cell-based anti-cancer immune response by targeting CT83 and HERV-K, tumor antigens expressed in triple-negative breast cancer. The UNITE platform is a technology that delivers tumor antigens to immune cells to activate T cells and induce an anti-cancer immune response.
"We will confirm the safety and immune response of ITI-5000 in the clinical trial and demonstrate its potential as a next-generation therapeutic cancer vaccine," said Kim Dong-gun, CEO of Immunomic Therapeutics.
HLB said on the 20th that Immunomic had begun dosing the first patient in a U.S. Phase 1 clinical trial of ITI-5000, a therapeutic cancer vaccine candidate for triple-negative breast cancer (TNBC). Immunomic received approval for its Phase 1 investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) in January this year.
In the trial, Immunomic will evaluate the safety, tolerability and early immunological activity of ITI-5000 in patients with stage 2-3 triple-negative breast cancer. The company decided to test the candidate both as a monotherapy and in combination with standard adjuvant therapy.
ITI-5000 is a cancer vaccine candidate that applies self-amplifying RNA (saRNA) technology based on "UNITE," an immunotherapy vaccine platform independently developed by Immunomic. It is designed to induce a T-cell-based anti-cancer immune response by targeting CT83 and HERV-K, tumor antigens expressed in triple-negative breast cancer. The UNITE platform is a technology that delivers tumor antigens to immune cells to activate T cells and induce an anti-cancer immune response.
"We will confirm the safety and immune response of ITI-5000 in the clinical trial and demonstrate its potential as a next-generation therapeutic cancer vaccine," said Kim Dong-gun, CEO of Immunomic Therapeutics.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。